Skip to main content

Home/ Nutrition/ Group items tagged thorne

Rss Feed Group items tagged

Matti Narkia

Zingiber officinale (Ginger) - Monograph - thorne.com - 0 views

  •  
    Zingiber officinale (ginger). Monograph. [No authors listed] Altern Med Rev. 2003 Aug;8(3):331-5. PMID: 12946242
Matti Narkia

Use of vitamin D in clinical practice. - Altern Med Rev. 2008 Mar - 0 views

  •  
    Use of vitamin D in clinical practice. Cannell JJ, Hollis BW. Altern Med Rev. 2008 Mar;13(1):6-20. PMID: 18377099 The recent discovery--from a meta-analysis of 18 randomized controlled trials--that supplemental cholecalciferol (vitamin D) significantly reduces all-cause mortality emphasizes the medical, ethical, and legal implications of promptly diagnosing and adequately treating vitamin D deficiency. Not only are such deficiencies common, and probably the rule, vitamin D deficiency is implicated in most of the diseases of civilization. Vitamin D's final metabolic product is a potent, pleiotropic, repair and maintenance, seco-steroid hormone that targets more than 200 human genes in a wide variety of tissues, meaning it has as many mechanisms of action as genes it targets. One of the most important genes vitamin D up-regulates is for cathelicidin, a naturally occurring broad-spectrum antibiotic. Natural vitamin D levels, those found in humans living in a sun-rich environment, are between 40-70 ng per ml, levels obtained by few modern humans. Assessing serum 25-hydroxy-vitamin D (25(OH)D) is the only way to make the diagnosis and to assure treatment is adequate and safe. Three treatment modalities exist for vitamin D deficiency: sunlight, artificial ultraviolet B (UVB) radiation, and vitamin D3 supplementation. Treatment of vitamin D deficiency in otherwise healthy patients with 2,000-7,000 IU vitamin D per day should be sufficient to maintain year-round 25(OH)D levels between 40-70 ng per mL. In those with serious illnesses associated with vitamin D deficiency, such as cancer, heart disease, multiple sclerosis, diabetes, autism, and a host of other illnesses, doses should be sufficient to maintain year-round 25(OH)D levels between 55 -70 ng per mL. Vitamin D-deficient patients with serious illness should not only be supplemented more aggressively than the well, they should have more frequent monitoring of serum 25(OH)D and serum calcium. Vitamin D should always be
Matti Narkia

Therapeutic applications of whey protein - 136.pdf (application/pdf Object) - 0 views

  •  
    Marshall K. Therapeutic applications of whey protein. Altern Med Rev. 2004 Jun;9(2):136-56. Review. PMID: 15253675 [PubMed - indexed for MEDLINE]
Matti Narkia

Benefits and requirements of vitamin D for optimal health: a review - Altern Med Rev. 2... - 0 views

  •  
    Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005 Jun;10(2):94-111. Review. PMID: 15989379 [PubMed - indexed for MEDLINE]
Matti Narkia

Antioxidants and Cancer III: Quercetin (PDF) - 0 views

  •  
    Antioxidants and Cancer III: Quercetin Davis W. Lamson, MS, ND, and Matthew S. Brignall, ND Alternative Medicine Review ◆ Volume 5, Number 3 ◆ 2000. review
Matti Narkia

Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disea... - 0 views

  •  
    Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Kidd P. Altern Med Rev. 2003 Aug;8(3):223-46. Review. PMID: 12946237 Th1 pathways typically produce activation of cytotoxic T lymphocytes (Tc), NK cells, macrophages, and monocytes, all of which can attack cancer cells and generally defend against tumors. 55 IFN-gamma and other Th1 cytokines are typically lower in advanced cancer patients, while the Th2 marker IL-4 can be higher or unchanged.56 Nodules of non-small cell lung cancer freshly removed from patients expressed a marked imbalance toward Th2, as did biopsy samples from basal cell carcinoma.57 In prostate cancer patients IL-2 was low (Th1) and IL-10 high.58 IL-10 is a confirmed Th1-suppressive cytokine, and heightened IL-10 is a common factor in cancer.55 IL-10 has a variety of suppressive effects that include inhibiting Th1 cytokine production, down-regulating APC and NK cell function, and lowering overall T-cell proliferation.57 Especially under the influence of IL-4 (Th2), tumor cells apparently up-regulate IL-10 that suppresses nearby killer cells. Tumor-derived IL-10 has been documented in lymphoma, ovarian carcinoma, melanoma, neuroblastoma, and renal cell and colon carcinoma.57 IL-12 is another cytokine that can be up-regulated by Th1 activity and inhibited by Th2.59 A low IL-12/IL-10 ratio was found in cervical cancer patients.55 Recent clinical studies suggest elevated IL-10 is predictive of a poor prognosis. 57 With both IL-4 and IL-10 being proven inhibitors of Th1 and promoters of Th2 activity, the recognized capability of cancerous tissue to suppress immunity is readily rationalized.
Matti Narkia

Berberine - Altern Med Rev. 2000 Apr;5(2):175-7. - 0 views

  •  
    Berberine. [No authors listed] Altern Med Rev. 2000 Apr;5(2):175-7. PMID: 10767672 Berberine is a plant alkaloid with a long history of medicinal use in both Ayurvedic and Chinese medicine. It is present in Hydrastis canadensis (goldenseal), Coptis chinensis (Coptis or goldenthread), Berberis aquifolium (Oregon grape), Berberis vulgaris (barberry), and Berberis aristata (tree turmeric). The berberine alkaloid can be found in the roots, rhizomes, and stem bark of the plants. Berberine extracts and decoctions have demonstrated significant antimicrobial activity against a variety of organisms including bacteria, viruses, fungi, protozoans, helminths, and chlamydia. Currently, the predominant clinical uses of berberine include bacterial diarrhea, intestinal parasite infections, and ocular trachoma infection
Matti Narkia

Vitamin K2. Monograph. - Altern Med Rev. 2009 Sep;14(3):284-93 - 1 views

  •  
    Vitamin K2. Monograph. [No authors listed] Altern Med Rev. 2009 Sep;14(3):284-93. Review. PMID: 19803553
Matti Narkia

Phosphatidylserine. Monograph. - Altern Med Rev. 2008 Sep;13(3):245-7. - 0 views

  •  
    Phosphatidylserine. Monograph.\nAltern Med Rev. 2008 Sep;13(3):245-7. \nPMID: 18950250 [PubMed - indexed for MEDLINE]
Matti Narkia

379.pdf (application/pdf Object) - 0 views

  •  
    Pantethine. Altern Med Rev. 1998 Oct;3(5):379-81. PMID: 9802914 [PubMed - indexed for MEDLINE]
1 - 20 of 21 Next ›
Showing 20 items per page